A Science & Innovation Webinar, presented by Jazz Pharmaceuticals.

This webinar will explore the role of HER2 as an actionable biomarker in Biliary tract cancer (BTC), and highlight recent clinical data supporting HER2-targeted therapies. Managed care professionals will gain insights into the evolving treatment landscape, the importance of timely access to molecular testing and therapy, and strategies to optimize coverage decisions. Join us for a timely discussion on how managed care professionals can support improved outcomes for patients with HER2-positive BTC.

A Science & Innovation Webinar, presented by GSK.

This educational session provides an up-to-date overview of chronic hepatitis B (CHB), focusing on its epidemiology, disease burden, and the evolving goal of achieving a functional cure. The program highlights the challenges of CHB management, the importance of early detection and guideline-based care, and the psychosocial impact on patients. Current gaps in diagnosis and treatment are discussed, along with the rationale for aiming beyond viral suppression toward functional cure as recommended by global guidelines.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Sanofi.

In this webinar, we will be discussing the following topics around T1D staging, screening, and treatment:

• The role of beta-cell function and C-peptide in disease progression.
• Mechanism of action for teplizumab.
• Efficacy and safety results from teplizumab clinical development program.

This product is indicated for use in State 2 T1D patients aged 8 years and older to delay onset of Stage 3 T1D. The data in this webinar regarding the use in Stage 3 T1D patients is investigational and the safety and efficacy for this use has not been reviewed/approved by the FDA. This information constitutes preapproval information exchange and is intended for formulary/population health decision makers only.

This webinar will provide payer and managed care leaders with a clear, visual map of the precision medicine patient access ecosystem, illuminate the roles and handoffs that drive delays, and define specific payer levers, including equity-focused measures, to reduce friction and accelerate timeline, equitable access.

A Science & Innovation Webinar, presented by Abbvie.

Migraine is a complex, chronic disease that results in significant patient and economic burden. Migraine ranks second worldwide in terms of years lost due to disability. Direct annual all cause healthcare costs for a migraine patient is over twice that of a non-migraine patient. Indirect costs from the impact of the disease on a patient's ability to function (absenteeism and presenteeism) total over $35B annually.

Therefore, it is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal.